SERPINB2, also known as plasminogen activator inhibitor type 2 (PAI-2), has been shown to be directly related to tumor promotion and poor prognosis in various cancers such as bladder [11], colorectal [12], endometrial [13] and ovarian [14] cancers. Here, SERPINB2 is linked to cancer.